LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (BrightSpring or BrightSpring Health Services) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the...
LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (€œBrightSpring€ or €œBrightSpring Health Services€) (NASDAQ: BTSG) announced today that its company Onco360®, a...
Onco360® Celebrates Excellent Patient Care and Preferred Pharmacy Status
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO
FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
OGSIVEO Available from Onco360 as First and Only Treatment for Desmoid Tumors
TRUQAP™ (capivasertib) Now Available from Onco360
FRUZAQLA™ (fruquintinib) Now Available from Onco360
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
OJJAARA™ (momelotinib) Now Available from Onco360 For the Treatment of Intermediate or High-Risk Myelofibrosis (MF), Including Primary MF or Secondary MF [Post-Polycythemia Vera (PV) and Post- Essential Thrombocythemia (ET)], in Adults with Anemia